Stocktoria
Genenta Science S.p.A. GNTA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-12-15
Genenta Science S.p.A. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $2.7M | $4.8M | $6.5M | $5.3M | $3.4M |
| Operating income | -$6.6M | -$9.8M | -$11.7M | -$11.0M | -$5.7M |
| Net income | -$6.5M | -$8.9M | -$11.6M | -$8.5M | -$5.5M |
| EPS (diluted) | $-0.33 | $-0.49 | $-0.64 | $-0.47 | $-0.37 |
| Operating cash flow | -$6.9M | -$6.2M | -$11.2M | -$7.4M | -$7.0M |
| Free cash flow | -$6.9M | -$6.2M | -$11.2M | -$7.4M | -$7.0M |
| Cash & equivalents | $5.5M | $4.6M | $3.7M | $29.8M | $25.7M |
| Total assets | $31.9M | $14.8M | $22.3M | $33.4M | $40.0M |
| Shareholders' equity | $21.8M | $12.5M | $20.4M | $31.1M | $38.9M |
Source: SEC EDGAR filings · CIK 0001838716 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.